Building a world where
tomorrow is another day!

Home
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • May 15, 2025 Notice Concerning Change of Major Shareholder pdf (249KB)
  • Apr 28, 2025 Notice of Discontinuation of Development of CTX-177 (ONO-7018) pdf (289KB)
  • Apr 25, 2025 Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025 pdf (229KB)
  • Apr 24, 2025 Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025 pdf (276KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Investor Relations
Investor Relations

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

People

People

Contact

Contact

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box